A complete surgical resection currently represents the only curative treatment option fir gastric carcinoma, but as regards locally advanced cancer the possibility of local or distant recurrence remains extremely high even following a RO resection. As far as T3-4 / N+ tumors are concerned unsatisfying results of surgery alone have stressed the need for multimodal treatments: in the recent past adjuvant chemotherapy has represented a common complementary treatment for locally advanced gastric cancer, but conclusive results of most randomized trials did not show a significant impact on long term survival. Literature review shows a growing trend throughout the 90s towards the adoption of a preoperative chemotherapy initially evaluated as a form af "salvage" palliative treatment for unresectable patients. To date a number of phase II study suggests the efficacy of neo-adjuvant treatment administered to resectable patients with the purpose of inducing tumor downstaging, increasing the rate of RO resections and controlling recurrencies. From March 1996 the Authors have started a controlled study on neo-adjuvant therapy for locally advanced gastric cancer. Accurate staging and patients selection were based upon immediately preoperative laparoscopy. In this ongoing study, patients are administered two preoperative cycles of EEP chemotherapy (Etoposide, Epirubicin, cii-Platin). Preliminary data have been evaluated on the first 15 cases. Grade I myelosupression has been observed in 12/15 cases and grade II/III in 3/15 cases; 1 patient died by septic complications. Restaging has not shown progression of the disease in 13/14 cases; a macroscopic response was evidenced in 7/14 patients; 14/14 patients couid undergo a successful D2 surgical resection following neo-adjuvant therapy. Pathological staging confirmed tumor downstaging in 7 out of 14 cases; 12/14 patients in this group (85.7%) could benefit a RO resection. These preliminary data encourage us to proceed in our prospective investigation.
D'Ugo, D., Persiani, R., Pende, V., Picciocchi, A., Neoadjuvant chemotherapy for gastric carcinoma, <<ANNALI ITALIANI DI CHIRURGIA>>, 2020; 72 (1): 47-53 [http://hdl.handle.net/10807/173177]
Neoadjuvant chemotherapy for gastric carcinoma
D'Ugo, Domenico;Persiani, Roberto;
2001
Abstract
A complete surgical resection currently represents the only curative treatment option fir gastric carcinoma, but as regards locally advanced cancer the possibility of local or distant recurrence remains extremely high even following a RO resection. As far as T3-4 / N+ tumors are concerned unsatisfying results of surgery alone have stressed the need for multimodal treatments: in the recent past adjuvant chemotherapy has represented a common complementary treatment for locally advanced gastric cancer, but conclusive results of most randomized trials did not show a significant impact on long term survival. Literature review shows a growing trend throughout the 90s towards the adoption of a preoperative chemotherapy initially evaluated as a form af "salvage" palliative treatment for unresectable patients. To date a number of phase II study suggests the efficacy of neo-adjuvant treatment administered to resectable patients with the purpose of inducing tumor downstaging, increasing the rate of RO resections and controlling recurrencies. From March 1996 the Authors have started a controlled study on neo-adjuvant therapy for locally advanced gastric cancer. Accurate staging and patients selection were based upon immediately preoperative laparoscopy. In this ongoing study, patients are administered two preoperative cycles of EEP chemotherapy (Etoposide, Epirubicin, cii-Platin). Preliminary data have been evaluated on the first 15 cases. Grade I myelosupression has been observed in 12/15 cases and grade II/III in 3/15 cases; 1 patient died by septic complications. Restaging has not shown progression of the disease in 13/14 cases; a macroscopic response was evidenced in 7/14 patients; 14/14 patients couid undergo a successful D2 surgical resection following neo-adjuvant therapy. Pathological staging confirmed tumor downstaging in 7 out of 14 cases; 12/14 patients in this group (85.7%) could benefit a RO resection. These preliminary data encourage us to proceed in our prospective investigation.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
